Mechelen, Belgium; 19 May 2016 - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises.
Galapagos issued 140,770 new ordinary shares on 19 May 2016, for a total capital increase (including issuance premium) of €1,476,401.70.
CEO Onno van de Stolpe exercised 90,000 warrants that were due to expire this month for a total of €895,500 and has held the resulting shares. He consequently increased his holding to a total of 628,289 Galapagos shares. In addition to Onno van de Stolpe, one other Board member exercised 7,500 warrants. Moreover, pursuant to the warrant exercise program of Galapagos' Executive Committee, Executive Committee members automatically are committed to exercise a minimum number of warrants, subject to certain conditions. Pursuant to the rules of this program, two Executive Committee members exercised an aggregate number of 5,000 warrants, also to hold as shares.
In accordance with Belgian transparency legislation[1], Galapagos notes that its total share capital currently amounts to €249,394,222.78; the total number of securities conferring voting rights is 46,109,508, which is also the total number of voting rights (the "denominator"), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights is 2,981,227, which equals the total number of voting rights that may result from the exercise of these warrants. Galapagos does not have any convertible bonds or shares without voting rights outstanding.
About Galapagos
Galapagos(Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our maturing pipeline comprises Phase 2, Phase 1, pre-clinical and discovery studies in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world. Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 440 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. More information at www.glpg.com.
Galapagos issued 140,770 new ordinary shares on 19 May 2016, for a total capital increase (including issuance premium) of €1,476,401.70.
CEO Onno van de Stolpe exercised 90,000 warrants that were due to expire this month for a total of €895,500 and has held the resulting shares. He consequently increased his holding to a total of 628,289 Galapagos shares. In addition to Onno van de Stolpe, one other Board member exercised 7,500 warrants. Moreover, pursuant to the warrant exercise program of Galapagos' Executive Committee, Executive Committee members automatically are committed to exercise a minimum number of warrants, subject to certain conditions. Pursuant to the rules of this program, two Executive Committee members exercised an aggregate number of 5,000 warrants, also to hold as shares.
In accordance with Belgian transparency legislation[1], Galapagos notes that its total share capital currently amounts to €249,394,222.78; the total number of securities conferring voting rights is 46,109,508, which is also the total number of voting rights (the "denominator"), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights is 2,981,227, which equals the total number of voting rights that may result from the exercise of these warrants. Galapagos does not have any convertible bonds or shares without voting rights outstanding.
About Galapagos
Galapagos(Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our maturing pipeline comprises Phase 2, Phase 1, pre-clinical and discovery studies in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world. Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 440 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. More information at www.glpg.com.
